Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT003/PT005/PT001 versus placebo in moderate to very severe COPD
2014-004712-10Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glycopyrronium and formoterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pearl Therapeutics. Primary endpoint: Trough forced expiratory volume in 1 second (FEV1). Started Jul 2015; status: completed.
02
Drugs
glycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-004712-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004712-10.